Zentalis Pharmaceuticals Inc. (ZNTL): Price and Financial Metrics
ZNTL Price/Volume Stats
| Current price | $2.24 | 52-week high | $18.07 |
| Prev. close | $2.39 | 52-week low | $2.16 |
| Day low | $2.16 | Volume | 3,170,700 |
| Day high | $2.41 | Avg. volume | 1,914,891 |
| 50-day MA | $3.26 | Dividend yield | N/A |
| 200-day MA | $5.73 | Market Cap | 159.63M |
ZNTL Stock Price Chart Interactive Chart >
Zentalis Pharmaceuticals Inc. (ZNTL) Company Bio
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
ZNTL Price Returns
| 1-mo | -25.33% |
| 3-mo | -32.53% |
| 6-mo | -48.62% |
| 1-year | -83.77% |
| 3-year | -96.00% |
| 5-year | N/A |
| YTD | -26.07% |
| 2024 | -80.00% |
| 2023 | -24.78% |
| 2022 | -76.04% |
| 2021 | 61.84% |
| 2020 | N/A |
Loading social stream, please wait...